GlassScriptPhysician profile
David S Lessen
NPI 1871518373
$206,025.35
in general payments reported to CMS, 2019-2025
24 companies · $567 in 2025
The $567 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $158K · 2020: $47K · 2021: $98.92 · 2022: $168 · 2023: $137 · 2024: $490 · 2025: $567.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,078 · Education: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,077.71 |
| Education | $115.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $170,292.22 | 2019-2025 | Jakafi, Niktimvo |
| Amgen INC. | $31,946.73 | 2019-2022 | |
| Celgene Corporation | $1,559.06 | 2020-2024 | Pomalyst |
| Bayer Healthcare Pharmaceuticals INC. | $900.00 | 2020 | |
| Janssen Biotech, INC. | $548.59 | 2020-2025 | Darzalex, Talvey, Tecvayli |
| Pfizer INC. | $188.68 | 2019-2025 | |
| Genzyme Corporation | $84.75 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $59.51 | 2024-2025 | Opdivo, Reblozyl |
| Novartis Pharmaceuticals Corporation | $49.89 | 2019-2024 | |
| Servier Pharmaceuticals LLC | $48.99 | 2024-2025 | |
| Glaxosmithkline, LLC. | $43.89 | 2022-2023 | Shingrix |
| Daiichi Sankyo INC. | $42.76 | 2025 | Enhertu, Datroway |
| Abbvie INC. | $32.45 | 2025 | |
| Aveo Pharmaceuticals, INC. | $31.42 | 2024 | |
| Rigel Pharmaceuticals, INC. | $26.70 | 2025 | Gavreto, Tavalisse, Rezlidhia |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tactile Systems Technology INC | $26.45 | 2024 | Entre Plus, Flexitouch Plus |
| Myovant Sciences INC. | $23.93 | 2021 | |
| Genmab U.S., INC. | $18.92 | 2023 | Epkinly |
| Taiho Oncology, INC. | $18.73 | 2024 | |
| Adc Therapeutics America, INC. | $18.42 | 2024 | |
| Beigene USA, INC. | $17.17 | 2024 | Tevimbra |
| Adaptive Biotechnologies Corporation | $16.23 | 2025 | Clonoseq |
| Janssen Pharmaceuticals, INC | $15.99 | 2025 | |
| Aurobindo Pharma USA, INC. | $13.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Lessen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.